Company intelligence / Profile preview

Oncos Therapeutics

Helsinki, Uusimaa, Finland

Ownership: Private
Development stage: Phase 1

Overview

The lead product candidate ONCOS-102 successfully completed Phase I trials, demonstrating safety and promising immune activation. The pipeline included additional programs for various solid tumors using the same adenovirus-based technology.

Therapeutic areas: Oncology
Modalities: Oncolytic virusesgene therapy
Industry: Biotech

Drug pipeline

1 asset

CGTG-102

Phase 1

Indications: Solid tumors

Beyond the preview

Go deeper on Oncos Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncos Therapeutics.

Explore the full profile